|Videos|October 27, 2022
Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Advertisement
Episodes in this series
Advertisement
Related to this article
Mipletamig plus venetoclax and azacitidine delivers 93% clinical benefit in TP53-mutated frontline AML, fueling hopes for a new option.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
4
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
5